ArticleClinics in orthopedic surgery2025
Effects of Osteoporosis Medication Use on Reprocedure Rates Following Vertebral Augmentation: A Nationwide Cohort Study.
Article in Clinics in orthopedic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgroud: In this study, we aimed to investigate the effects of osteoporosis medication use and prescription duration on the rates of reprocedures for re-fractures in patients who underwent vertebral augmentation (VA). Methods: This retrospective cohort study was conducted using data collected from the National Health Insurance Service database of South Korea. Patients aged 50 years or older who underwent VA in 2012 were included in this study. A reprocedure was defined as an additional VA performed for re-fractures during a follow-up period of up to 5 years. Patients were categorized based on medication type (bisphosphonates, selective estrogen receptor modulators [SERMs], calcium supplements, or vitamin D supplements) and prescription duration (incomplete, complete, or absolute complete). The results were statistically analyzed using Cox regression and Kaplan-Meier survival analyses. Results: Among 9,070 patients included, 678 patients (7.5%) underwent reprocedures for re-fractures, with 41.0% of reprocedures performed within 6 months after VA. The reprocedure rate was higher in patients prescribed calcium or vitamin D supplements (13.3%) than in those prescribed bisphosphonates (7.7%) or SERMs (8.6%). Multivariate analysis revealed that prolonged prescription duration was associated with higher reprocedure rates, reflecting greater disease severity. The absolute complete prescription group showed a 9.07 times higher hazard ratio for reprocedure than the no-medication group. Conclusions: These findings highlight the potential of osteoporosis medication use and prescription duration as predictive factors for reprocedure rates after VA. Although patients with more severe osteoporosis require longer treatment, adherence to therapy may help reduce the risk of additional interventions over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.